



Biotech Daily

Friday July 8, 2016

Daily news on ASX-listed biotechnology companies

- * **ASX FLAT, BIOTECH UP: LIVING CELL UP 20.5%, PRANA DOWN 9%**
- * **INNATE OVERSUBSCRIBED RIGHTS ISSUE RAISES \$3m, TOTAL \$5.5m**
- * **BPH RAISES \$627k**
- * **US BLOOD BANK EXTENDS ITL SAMPLOK CONTRACT**
- * **REVA DIRECTORS, INVESTORS TAKE VISIUM'S 1.4%**

MARKET REPORT

The Australian stock market edged up 0.05 percent on Friday July 8, 2016 with the ASX200 up 2.6 points to 5,230.5 points.

Nineteen of the Biotech Daily Top 40 stocks were up, 12 fell, six traded unchanged and three were untraded. All three Big Caps fell.

Living Cell was the best, up 1.7 cents or 20.5 percent to 10 cents, with 3.1 million shares traded, followed by Osprey up 18 percent to 29.5 cents with 449,393 shares traded.

Actinogen climbed 9.9 percent; Prima and Reva were up more than seven percent; Admedus was up 6.1 percent; Ellex improved 5.7 percent; Cellmid, Mesoblast and Pharmaxis were up more than three percent; Airxpanders, Opthea and Sirtex rose more than two percent; Compumedics was up 1.3 one percent; with Acrux, Impedimed, Nanosonics, Pro Medicus and Viralytics up by less than one percent.

Prana led the falls, down one cent or 9.1 percent to 10 cents, with 138,262 shares traded.

Universal Biosensors lost 8.3 percent; Anteo fell five percent; Neuren shed 4.55 percent; Antisense, Atcor and Orthocell were down more than three percent; Starpharma shed 2.3 percent; Avita, Biotron and Medical Developments were down one percent or more; with Clinuvel, Cochlear, CSL and Resmed down by less than one percent.

INNATE IMMUNOTHERAPEUTICS

Innate says its one-for-nine rights issue at 25 cents a share, to raise up to \$3,025,000, was oversubscribed, with applications for 19,651,896 shares.

Innate said that the rights offer raised \$1,970,190 through applications for 7,880,760 shares, with applications for 11,771,136 shares beyond the one-for-nine entitlement.

The company said that the additional share applications would be scaled back.

Innate chief executive officer Simon Wilkinson said the company was "very pleased with the outcome of the rights issue".

In June, the company said it had raised \$US1,801,635 (\$A2,429,628) in a placement to US investors, taking the total capital raised to \$5,454,628 (BD: Jun 10, 2016).

Innate fell two cents or 4.55 percent to 42 cents.

BPH ENERGY

BPH says it has raised \$626,993 in a placement and share plan at 0.533 cents a share. BPH said the share plan raised \$376,993 through the issue of 70,730,318 shares and it had "finalised agreements to raise approximately \$250,000 in a private placement ... to sophisticated and professional investors" at 0.533 cents a share.

BPH said that "due to the overwhelming response to this capital raising the directors are reviewing alternative fundraising options that may be non-dilutive to existing shareholders".

In June, the company said it hoped to raise up to \$300,000 for three investee companies (BD: Jun 1, 2016).

BPH said the funds would be used to assist Cortical Dynamics commercialize and distribute its Brain Anaesthesia Monitor; support Molecular Discovery Systems validate HLS5 as a novel tumor suppressor gene for liver cancer; and fund Advent Energy preparatory work for a seismic survey in the offshore Sydney Basin for gas exploration.

BPH fell 0.3 cents or 33.3 percent to 0.6 cents with 16.7 million shares traded.

ITL

ITL says that an unnamed US community blood bank it has supplied for more than three years has extended its Samplok sampling kit contract for a further 14 months.

ITL said that the sampling kit was used to transfer platelet samples when performing bacterial detection testing.

The company ITL said that the contract extension was in line its strategy to maintain strong sales of the Samplok sampling kit in the US, while reaching new markets.

ITL said that earlier this year the Orlando, Florida-based Oneblood blood bank also adopted the Samplok sampling kit (BD: Mar 21, 2016).

The company said the Samplok sampling kit had been granted patent protection as well as regulatory approval in the US and Taiwan and had won its first contract in Taiwan.

ITL executive chairman Bill Mobbs said that the "contract extension with one of the largest US community-based blood collection organizations ... is a very good achievement for ITL Biomedical".

"We are very pleased with the growth in sales and acceptance of [the Samplok sampling kit] that are paving the way for further successes through the year," Mr Mobbs said.

ITL was unchanged at 16.5 cents.

REVA MEDICAL

Reva says that several directors and institutional investors will buy Visium Balanced Master Fund shares in a private transaction.

Reva said that Visium was an investment fund in the process of liquidation and the shares amount to amounting to 1.4 percent of Reva would be bought at 98 cents each.

Reva was up eight cents or 7.5 percent to \$1.15.